EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Mechanism and rational combinations with GP ‐2250, a novel oxathiazine derivative, in ovarian cancer

Mark S Kim iD, Deanna Glassman, Katelyn F Handley, Adrian Lankenau Ahumada, Nicholas B Jennings, Emine Bayraktar, Katherine Foster, Robiya Joseph, Sanghoon Lee, Robert L Coleman, Anil K Sood iD

Cancer Medicine · 2024

DOI: 10.1002/cam4.70031 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2024. Verfasst von Mark S Kim und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Hauptthemen laut MEDLINE: Ovarian Neoplasms, Xenograft Model Antitumor Assays. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Cancer Prevention and Research Institute of Texas, Panavance Therapeutics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

GP‐2250, a novel analog of taurultam (TRLT), has emerged as a potent anti‐neoplastic drug; however, the mechanisms underlying its effects are not well understood. Here, we investigated the mechanism of action and the biological effects of GP‐2250 using in vitro and in vivo models.

Methods

We carried out a series of in vitro (MTT assay, Annexin V/PI assay, colony formation assay, reverse‐phase protein array [RPPA], and HRLC/IC analysis) to determine the biological activity of GP‐2250 and investigate the mechanism of action. In vivo experiments were carried out to determine the therapeutic efficacy of GP‐2250 alone and in combination with standard‐of‐care drugs (e.g., paclitaxel, cisplatin, topotecan, and poly ADP‐ribose polymerase [PARP] inhibitors).

Results

We investigated the cytotoxic effect of GP‐2250 in 10 ovarian cancer cell lines and found GP‐2250 combined with a PARP inhibitor had the greatest synergy. RPPA revealed that GP‐2250 inhibited hypoxia‐inducible factor‐1α, AKT, and mammalian target of rapamycin (mTOR) activation and expression. High‐resolution mass spectrometry revealed that hexokinase2 activity and protein expression were significantly reduced by GP‐2250 exposure. Furthermore, GP‐2250 reduced glycolysis and ATP synthesis in cancer cells. An in vivo pharmacodynamic experiment using the OVCAR8 mouse model demonstrated that 500 mg/kg GP‐2250 was effective in downregulating AKT and mTOR activation and expression. In the in vivo therapy experiment using an orthotopic mouse model, a combination of GP‐2250 with either PARP inhibitors or bevacizumab showed a significant reduction of tumor weights and nodules compared to those treated with a vehicle, control IgG groups, or monotherapy groups.

Conclusions

Taken together, our data indicate that GP‐2250 exerts profound effects on tumor metabolism and, in combination with PARP inhibitors or bevacizumab, showed promising anti‐tumor efficacy. These findings could have implications for the clinical development of GP‐2250.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ovarian NeoplasmsXenograft Model Antitumor AssaysAnimalsFemaleHumansMiceCell Line, TumorAntineoplastic Combined Chemotherapy ProtocolsDrug SynergismApoptosisCell ProliferationAntineoplastic AgentsDisease Models, AnimalHypoxia-Inducible Factor 1, alpha SubunitTOR Serine-Threonine KinasesPoly(ADP-ribose) Polymerase Inhibitors

Stichwörter der Autor:innen

GP‐2250PARP inhibitoranti‐neoplastic drugbevacizumabovarian cancer

Substanzen

Antineoplastic AgentsHypoxia-Inducible Factor 1, alpha SubunitTOR Serine-Threonine KinasesPoly(ADP-ribose) Polymerase Inhibitors

Autor:innen und Institutionen

  • Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • Department of Gynecologic Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, USA.
  • Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Morsani College of Medicine, University of South Florida, Tampa, Florida, USA.
  • MD Anderson Cancer Center UTHealth Graduate School of Biomedical Sciences Houston, Houston, Texas, USA.
  • US Oncology Research, The Woodlands, Texas, USA.

ORCID-Profile: Mark S Kim, Anil K Sood

Förderung

  • NCI NIH HHS
  • Cancer Prevention and Research Institute of Texas
  • Panavance Therapeutics
  • National Cancer Institute

Zitieren

APA

Kim, M. S., Glassman, D., Handley, K. F., Lankenau Ahumada, A., Jennings, N. B., Bayraktar, E., Foster, K., Joseph, R., Lee, S., Coleman, R. L., & Sood, A. K. (2024). Mechanism and rational combinations with GP ‐2250, a novel oxathiazine derivative, in ovarian cancer. Cancer Medicine. https://doi.org/10.1002/cam4.70031

Vancouver

Kim MS, Glassman D, Handley KF, Lankenau Ahumada A, Jennings NB, Bayraktar E, et al. Mechanism and rational combinations with GP ‐2250, a novel oxathiazine derivative, in ovarian cancer. Cancer Medicine. 2024. doi:10.1002/cam4.70031

BibTeX
@article{Kim2024,
  author = {Kim, Mark S and Glassman, Deanna and Handley, Katelyn F and Lankenau Ahumada, Adrian and Jennings, Nicholas B and Bayraktar, Emine and Foster, Katherine and Joseph, Robiya and Lee, Sanghoon and Coleman, Robert L and Sood, Anil K},
  title = {Mechanism and rational combinations with GP ‐2250, a novel oxathiazine derivative, in ovarian cancer},
  journal = {Cancer Medicine},
  year = {2024},
  doi = {10.1002/cam4.70031}
}
Kostenlos starten →